The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
UMC Utrecht
ViroMissile, Inc.
AstraZeneca
Duke University
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Eli Lilly and Company
IDEAYA Biosciences
Institut du Cancer de Montpellier - Val d'Aurelle
Hospices Civils de Lyon
Alliance for Clinical Trials in Oncology
Daiichi Sankyo
Memorial Sloan Kettering Cancer Center
University of Nebraska
Eli Lilly and Company
Oscotec Inc.
Kidney Cancer Research Bureau
Adela, Inc
Second Life Therapeutics
University of Michigan
Innate Pharma
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
DualityBio Inc.
University of Colorado, Denver
M.D. Anderson Cancer Center
Maastricht University Medical Center
Maastricht Radiation Oncology
Washington University School of Medicine
3B Pharmaceuticals GmbH
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
Brigham and Women's Hospital
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
National Cancer Centre, Singapore
NGM Biopharmaceuticals, Inc
Merus B.V.
Columbia University
Tempus AI
Theratechnologies
Elevation Oncology
Seagen Inc.
Labcorp Corporation of America Holdings, Inc
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center